Welcome to our dedicated page for Sonnet BioTherapeutics Holdings SEC filings (Ticker: SONN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Sonnet BioTherapeutics Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Sonnet BioTherapeutics Holdings's regulatory disclosures and financial reporting.
Sonnet Biotherapeutics Holdings, Inc. filed Amendment No. 1 to its annual report for the year ended September 30, 2025 solely to substitute the correct Report of Independent Registered Public Accounting Firm; all underlying financial statements and disclosures remain unchanged.
The auditor, KPMG LLP, issued an unqualified opinion but emphasized substantial doubt about the company’s ability to continue as a going concern due to recurring losses, negative operating cash flows, and the need for substantial additional financing. A critical audit matter was identified around estimating accrued research and development expenses, including $0.6 million of accrued R&D as of September 30, 2025, reflecting significant judgment in assessing third‑party service provider costs.